Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZSTARYS vs ADDERALL 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
AZSTARYS is a prodrug that is converted to dexmethylphenidate primarily through enzymatic hydrolysis by carboxylesterase 1 (CES1). The active metabolite dexmethylphenidate is further metabolized primarily via deesterification to ritalinic acid, with minor hydroxylation pathways.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
Serdexmethylphenidate: 94% (bound to albumin); dexmethylphenidate: 15-20%.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
Serdexmethylphenidate: 5.6 L/kg; dexmethylphenidate: 2.7 L/kg. High Vd indicates extensive tissue distribution.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Oral: 100% for serdexmethylphenidate (prodrug); dexmethylphenidate from the prodrug is 87% bioavailable relative to equivalent dexmethylphenidate dose.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
e GFR 15-29 m L/min: not recommended; e GFR <15 m L/min: contraindicated. No dose adjustment for e GFR >=30 m L/min.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Age 6-12 years: initial 19.6 mg oral once daily; titrate weekly by 19.6 mg; max 78.4 mg. Age 13-17 years: same as adult dosing.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
No specific studies in elderly; initiate at low end of dosing range due to increased sensitivity to sympathomimetics. Monitor cardiovascular status.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
AZSTARYS has a high potential for abuse and misuse, which can lead to dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor closely for tachycardia and hypertension.,Psychiatric adverse events: May precipitate psychotic or manic symptoms in patients with no prior history, or exacerbate symptoms in those with pre-existing psychiatric disorders.,Priapism: Prolonged and painful erections may occur, requiring immediate medical attention.,Peripheral vasculopathy: Including Raynaud's phenomenon, monitor for digital changes.,Long-term suppression of growth: Monitor growth in pediatric patients during treatment.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Hypersensitivity to methylphenidate products or any component of AZSTARYS,Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Tics or family history of Tourette's syndrome,Severe anxiety, tension, or agitation
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
High-fat meals delay time to peak concentration (Tmax) by approximately 2 hours but do not affect overall exposure (AUC). Avoid alcohol as it may alter drug release characteristics. No specific food restrictions; can be taken with or without food.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) due to chronic exposure.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
Excreted in human milk; M/P ratio not established. Limited data suggest potential for adverse effects in nursing infants (e.g., irritability, poor feeding). Decision to breastfeed should weigh risks and benefits; consider alternative feeding if drug is essential.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
No established dose adjustments in pregnancy; however, increased clearance may reduce efficacy. Titrate to lowest effective dose. Consider alternative therapies if possible due to unknown risks.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a prodrug combination with immediate-release and delayed-release components. Onset of action occurs within 1 hour, and duration is approximately 13 hours. It can be taken with or without food, but high-fat meals delay peak concentration. Avoid use in patients with pre-existing cardiovascular disease, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Monitor for growth suppression in children, weight loss, and insomnia. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May exacerbate tics or Tourette syndrome. Use with caution in patients with seizure disorder or those taking CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) due to increased dexmethylphenidate exposure.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Take exactly as prescribed; do not crush or chew capsules.,Avoid alcohol while taking this medication.,Report any chest pain, shortness of breath, or palpitations immediately.,May cause dizziness or blurred vision; avoid driving until effects are known.,Use with caution in patients with history of drug dependence or abuse.,Keep out of reach of children; do not share medication.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZSTARYS vs ADDERALL 10, answered by our medical review team.
AZSTARYS is a CNS Stimulant that works by AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.. ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZSTARYS and ADDERALL 10 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZSTARYS is: Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.. The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZSTARYS and ADDERALL 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZSTARYS is classified as Category C. Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, . ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.